COVID-19, otherwise known as the novel coronavirus, has created a global pandemic with a high rate of transmission. Speed and certainty of detection within patient populations are key to identifying and isolating potential outbreaks and enabling the resumption of normal business and social activity.
AccessDx has a complete suite of clinical testing solutions that have been made available pursuant to the FDA's emergency use authorization for diagnostic testing. This includes COVID-19 Infection testing using RT-PCR technology, as well as high-quality COVID-19 IgG antibody testing using CMIA technology.
The AccessDx Covid-19 diagnostic test quickly identifies the presence of SARS-CoV-2 using a laboratory-grade RT-PCR testing process. Results are available within 24-48 hours of sample reciept.
In addition to base COVID-19 testing options, AccessDx also offers a comprehensive respiratory pathogen panel that detects 26 additional viral and bacterial infections.
*Download a PDF summary of AccessDx COVID-19 infection testing solutions.
The AccessDx COVID-19 Antibody test is designed to identify the presence of IgG antibodies from a patient's blood sample. This type of testing helps to identify those who have had previous exposure to the virus, even if that individual has been previously asymptomatic. AccessDx COVID-19 antibody testing can be utilized by healthcare providers and health agencies as part of their mitigation and tracking programs, as well as employer groups looking to assess potential outbreaks or faciliate return-to-work processes.
Here's how it works:
The AccessDx support team is highly experienced in rapid response scenarios, multi-facility deployments, and end-to-end testing program support for healthcare, community, and employer clients. No matter your group's unique needs, the AccessDx team is dedicated to addressing the challenges presented by COVID-19.
Contact the AccessDx COVID-19 hotline by phone or email for additional information.